Xcell Therapeutics and Gencurix to co-develop exosome-based brain disease diagnostic products

Original from: Korea Biomedical Review

Xcell Therapeutics is expanding the business scope of its exosome isolation and purification device, “EXODUS,” into the diagnostics market.

Last Friday, Xcell Therapeutics signed a joint development agreement with Gencurix, a molecular diagnostics company, to develop exosome diagnostic products.

EXODUS is a device developed based on Professor Luke P. Lee's exosome separation technology at Harvard University Medical School. Xcell Therapeutics has exclusive domestic sales rights.

Under the agreement, Xcell Therapeutics will provide commercialization rights to EXODUS, and Gencurix will discover exosome-derived biomarkers and develop diagnostic products. Xcell Therapeutics will make a strategic equity investment of 900 million won ($645,577) in Gencurix to support R&D and domestic and international business.

EXODUS is an automated equipment that separates and purifies exosomes with higher purity and yield than existing methods. Following the launch of the “EXODUS H-600” model in the second half of last year, Xcell Therapeutics launched the “T-2800,” a GMP-grade, high-capacity model with four times the processing speed, in September.

EXODUS can isolate high-purity exosomes from various samples, including blood, saliva, and urine, enabling rapid diagnosis at a reduced cost and patient burden compared to existing diagnostic methods. Exosomes are nano-sized cell-derived vesicles that contain disease-related information and are gaining attention as early diagnostic biomarkers for brain diseases, especially Alzheimer's and dementia.

“The collaboration with Gencurix expands the scope of EXODUS business from the development of therapeutic and cosmetic ingredients to the early diagnosis market,” Xcell Therapeutics CEO Lee Yi-il said. “We will respond to market demand by supplying innovative EXODUS equipment and exosome-based early diagnosis products to medical institutions at home and abroad."

Source: Xcell Therapeutics and Gencurix to co-develop exosome-based brain disease diagnostic products